An illustration shows the structure of an inhibitor bound to the active site of membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase. An inhibitor bound to the active site of ...
Last year’s landmark case of “Baby KJ”—the first patient to receive a personalized CRISPR‑based gene therapy—showcased both the promise and the persistent challenges of genome editing. While CRISPR ...